ArticleTheranostics2025

Combination of KRAS ASO and RIG-I agonist in extracellular vesicles transforms the tumor microenvironment towards effective treatment of KRAS-dependent cancers.

Cao Dai Phung et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.